Persons with dispensed medicines; origin
| Sex | Age | Origin | Medicine group (ATC) | Periods | Persons with medicines, relative (%) |
|---|---|---|---|---|---|
| Total male and female | Total age | Total | A07 Anti diarr/intest/infl/infect.agents | 2024* | 1.15 |
| Total male and female | Total age | Total | A07E Intestinal antiinflammatory agents | 2024* | 0.50 |
| Total male and female | Total age | Total | A14 Anabolic agents for systemic use | 2024* | 0.00 |
| Total male and female | Total age | Total | A14B Other anabolic agents | 2024* | 0.00 |
| Total male and female | Total age | Total | B01 Antithrombotic agents | 2024* | 10.81 |
| Total male and female | Total age | Total | B01A Antithrombotic agents | 2024* | 10.81 |
| Total male and female | Total age | Total | B06 Other hematological agents | 2024* | 0.00 |
| Total male and female | Total age | Total | B06A Other hematological agents | 2024* | 0.00 |
| Total male and female | Total age | Total | C02A Antiadren.agents, centrally acting | 2024* | 0.07 |
| Total male and female | Total age | Total | C02B Antiadren.agents, ganglion-blocking | 2024* | 0.00 |
| Total male and female | Total age | Total | C02C Antiadren.agents, peripher. acting | 2024* | 0.24 |
| Total male and female | Total age | Total | C02D Arteriolar smooth muscle agents | 2024* | 0.00 |
| Total male and female | Total age | Total | C03D Potassium-sparing agents | 2024* | 1.33 |
| Total male and female | Total age | Total | C03E Diuretics/potassium-sparing agents | 2024* | 0.05 |
| Total male and female | Total age | Total | C05A Topic agents hemorrh./anal fissures | 2024* | 0.32 |
| Total male and female | Total age | Total | C05C Capillary stabilizing agents | 2024* | 0.00 |
| Total male and female | Total age | Total | C07 Beta blocking agents | 2024* | 8.28 |
| Total male and female | Total age | Total | C07A Beta blocking agents | 2024* | 8.19 |
| Total male and female | Total age | Total | C07B Beta blocking agents and thiazides | 2024* | 0.08 |
| Total male and female | Total age | Total | C07C Beta block.agents / other diuretics | 2024* | 0.02 |
| Total male and female | Total age | Total | C07E Beta blocking agents / vasodilators | 2024* | 0.00 |
| Total male and female | Total age | Total | C09 Agents on renin-angiotensin system | 2024* | 11.62 |
| Total male and female | Total age | Total | C09X Other renin angiotensin syst.agents | 2024* | 0.03 |
| Total male and female | Total age | Total | C10 Lipid modifying agents | 2024* | 11.86 |
| Total male and female | Total age | Total | C10A Lipid modifying agents, plain | 2024* | 11.75 |
| Total male and female | Total age | Total | C10B Lipid modifying agents,combinations | 2024* | 0.14 |
| Total male and female | Total age | Total | H05B Anti-parathyroid agents | 2024* | 0.03 |
| Total male and female | Total age | Total | L Antineoplastic and immunomodul. agents | 2024* | 2.13 |
| Total male and female | Total age | Total | L01 Antineoplastic agents | 2024* | 0.63 |
| Total male and female | Total age | Total | L01A Alkylating agents | 2024* | 0.00 |
| Total male and female | Total age | Total | L01X Other antineoplastic agents | 2024* | 0.00 |
| Total male and female | Total age | Total | L02A Hormones and related agents | 2024* | 0.23 |
| Total male and female | Total age | Total | L02B Hormone antagonists/related agents | 2024* | 0.39 |
| Total male and female | Total age | Total | M01C Specific antirheumatic agents | 2024* | 0.00 |
| Total male and female | Total age | Total | N04A Anticholinergic agents | 2024* | 0.06 |
| Total male and female | Total age | Total | N04B Dopaminergic agents | 2024* | 0.46 |
| Total male and female | Total age | Total | N06B Psychostimul.,adhd agents,nootropic | 2024* | 1.78 |
| Total male and female | Total age | Total | P02C Antinematodal agents | 2024* | 0.54 |
| Total male and female | Total age | Total | S01B Antiinflammatory agents | 2024* | 1.55 |
| Total male and female | Total age | Total | S01J Diagnostic agents | 2024* | 0.00 |
| Total male and female | Total age | Total | S01L Ocular vascular disorder agents | 2024* | 0.00 |
| Total male and female | Total age | Total | V04 Diagnostic agents | 2024* | 0.00 |
| Total male and female | Total age | Total | V04C Other diagnostic agents | 2024* | 0.00 |
| Total male and female | Total age | Total | V10A Antiinflammatory agents | 2024* | 0.00 |
| Total male and female | Total age | Total | V10B Pain palliation,bone seeking agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | A07 Anti diarr/intest/infl/infect.agents | 2024* | 1.24 |
| Total male and female | Total age | Origin: born in the Netherlands | A07E Intestinal antiinflammatory agents | 2024* | 0.54 |
| Total male and female | Total age | Origin: born in the Netherlands | A14 Anabolic agents for systemic use | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | A14B Other anabolic agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | B01 Antithrombotic agents | 2024* | 11.67 |
| Total male and female | Total age | Origin: born in the Netherlands | B01A Antithrombotic agents | 2024* | 11.67 |
| Total male and female | Total age | Origin: born in the Netherlands | B06 Other hematological agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | B06A Other hematological agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | C02A Antiadren.agents, centrally acting | 2024* | 0.07 |
| Total male and female | Total age | Origin: born in the Netherlands | C02B Antiadren.agents, ganglion-blocking | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | C02C Antiadren.agents, peripher. acting | 2024* | 0.24 |
| Total male and female | Total age | Origin: born in the Netherlands | C02D Arteriolar smooth muscle agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | C03D Potassium-sparing agents | 2024* | 1.41 |
| Total male and female | Total age | Origin: born in the Netherlands | C03E Diuretics/potassium-sparing agents | 2024* | 0.06 |
| Total male and female | Total age | Origin: born in the Netherlands | C05A Topic agents hemorrh./anal fissures | 2024* | 0.29 |
| Total male and female | Total age | Origin: born in the Netherlands | C05C Capillary stabilizing agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | C07 Beta blocking agents | 2024* | 8.78 |
| Total male and female | Total age | Origin: born in the Netherlands | C07A Beta blocking agents | 2024* | 8.68 |
| Total male and female | Total age | Origin: born in the Netherlands | C07B Beta blocking agents and thiazides | 2024* | 0.08 |
| Total male and female | Total age | Origin: born in the Netherlands | C07C Beta block.agents / other diuretics | 2024* | 0.03 |
| Total male and female | Total age | Origin: born in the Netherlands | C07E Beta blocking agents / vasodilators | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | C09 Agents on renin-angiotensin system | 2024* | 12.21 |
| Total male and female | Total age | Origin: born in the Netherlands | C09X Other renin angiotensin syst.agents | 2024* | 0.03 |
| Total male and female | Total age | Origin: born in the Netherlands | C10 Lipid modifying agents | 2024* | 12.28 |
| Total male and female | Total age | Origin: born in the Netherlands | C10A Lipid modifying agents, plain | 2024* | 12.17 |
| Total male and female | Total age | Origin: born in the Netherlands | C10B Lipid modifying agents,combinations | 2024* | 0.15 |
| Total male and female | Total age | Origin: born in the Netherlands | H05B Anti-parathyroid agents | 2024* | 0.03 |
| Total male and female | Total age | Origin: born in the Netherlands | L Antineoplastic and immunomodul. agents | 2024* | 2.30 |
| Total male and female | Total age | Origin: born in the Netherlands | L01 Antineoplastic agents | 2024* | 0.72 |
| Total male and female | Total age | Origin: born in the Netherlands | L01A Alkylating agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | L01X Other antineoplastic agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | L02A Hormones and related agents | 2024* | 0.25 |
| Total male and female | Total age | Origin: born in the Netherlands | L02B Hormone antagonists/related agents | 2024* | 0.41 |
| Total male and female | Total age | Origin: born in the Netherlands | M01C Specific antirheumatic agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | N04A Anticholinergic agents | 2024* | 0.05 |
| Total male and female | Total age | Origin: born in the Netherlands | N04B Dopaminergic agents | 2024* | 0.51 |
| Total male and female | Total age | Origin: born in the Netherlands | N06B Psychostimul.,adhd agents,nootropic | 2024* | 2.00 |
| Total male and female | Total age | Origin: born in the Netherlands | P02C Antinematodal agents | 2024* | 0.54 |
| Total male and female | Total age | Origin: born in the Netherlands | S01B Antiinflammatory agents | 2024* | 1.63 |
| Total male and female | Total age | Origin: born in the Netherlands | S01J Diagnostic agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | S01L Ocular vascular disorder agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | V04 Diagnostic agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | V04C Other diagnostic agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | V10A Antiinflammatory agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in the Netherlands | V10B Pain palliation,bone seeking agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in NL, parents in NL | A07 Anti diarr/intest/infl/infect.agents | 2024* | 1.26 |
| Total male and female | Total age | Origin: born in NL, parents in NL | A07E Intestinal antiinflammatory agents | 2024* | 0.57 |
| Total male and female | Total age | Origin: born in NL, parents in NL | A14 Anabolic agents for systemic use | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in NL, parents in NL | A14B Other anabolic agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in NL, parents in NL | B01 Antithrombotic agents | 2024* | 12.67 |
| Total male and female | Total age | Origin: born in NL, parents in NL | B01A Antithrombotic agents | 2024* | 12.67 |
| Total male and female | Total age | Origin: born in NL, parents in NL | B06 Other hematological agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in NL, parents in NL | B06A Other hematological agents | 2024* | 0.00 |
| Total male and female | Total age | Origin: born in NL, parents in NL | C02A Antiadren.agents, centrally acting | 2024* | 0.07 |
| Total male and female | Total age | Origin: born in NL, parents in NL | C02B Antiadren.agents, ganglion-blocking | 2024* | 0.00 |
| Source: CBS. | |||||
Table explanation
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, origin, age and sex.
Data available from 2020
Status of the figures:
Figures for 2024 are provisional, figures for previous years are final.
Changes as of December 18, 2025:
- Provisional figures for 2024 have been added, provisional figures of 2023 have been made definite.
- Figures for 2024 do not include DDD's as they are insufficiently reliable.
When will new figures be published?
New figures will be published in the last quarter of 2026.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.